KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical trial for an oral on-demand therapy for acute HAE attacks; and KVD824, an oral product candidate for the treatment of HAE. The company is headquartered in Cambridge, Massachusetts.
IPO Year: 2015
Exchange: NASDAQ
Website: kalvista.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2022 | $48.00 → $42.00 | Buy | Needham |
| 12/10/2021 | $50.00 → $48.00 | Buy | Needham |
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
3 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
– Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours – – Safety profile comparable to placebo – – On track for submission of new drug application to U.S. FDA in the first half of 2024 – – Conference call to discuss trial results today at 8:30 a.m. ET – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat as oral on-demand therapy for hereditary angioedema (HAE). KONFIDENT was the l
HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $20 price target.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler cut the price target for Adobe Inc. (NASDAQ:ADBE) from $700 to $635. Piper Sandler analyst Brent Bracelin maintained an Overweight rating. Adobe shares fell 1.2% to close at $557.63 on Thursday. See how other analysts view this stock. Needham slashed the price target for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) from $35 to $32. Needham analyst Serge Belanger maintained a Buy rating. KalVista Pharmaceuticals shares fell 0.6% to close at $12.50 on Thursday. See how other analysts vi
Needham analyst Serge Belanger maintains KalVista Pharma (NASDAQ:KALV) with a Buy and lowers the price target from $35 to $32.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and released financial results for the fiscal year ended April 30, 2024. "This last fiscal quarter was the most important in the history of KalVista," said Ben Palleiko, CEO of KalVista. "Not only did we submit the NDA for sebetralstat to the FDA, but the KONFIDENT phase 3 trial results were published in The New England Journal of Medicine, supporting our view on the importance of this potential therapy. We look forward to building on these milestones as we submit additional marketing authorization applications to other national health authorities throughout 2024 and anticipate approval and launch in the US i
If approved, sebetralstat would be the first oral on-demand therapy in pediatric patients aged 2 – 11 years, and only the second FDA-approved on-demand therapy of any type in this population.
Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.
Sebetralstat is a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 years and older. The FDA has a 60-day filing review period to determine whether the NDA is complete and accepted for review. The Company currently anticipates receiving notification from the FDA on the status of the submission in September. KalVista intends to submit additional marketing authorization applications to other global health authorities throughout 2024.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the European Academy of Allergy and Clinical Immunology Congress 2024 that took place in Valencia, Spain. The following presentations occurred at EAACI 2024: Hereditary Angioedema (HAE) Patients Answer: Why Do Attacks Go Untreated? Cristine Radojicic, Division of Pulmonary, Allergy and Critical Care, Duke University Medical Center, Durham, North Carolina, USA. (Flash Talks Session) For 50% of US survey respondents with HAE, their untreated attack progressed in severity while 25% o
Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $42.00 from $48.00 previously
Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $48.00 from $50.00 previously
SVB Leerink resumed coverage of KalVista Pharmaceuticals with a rating of Buy
Roth Capital reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $55.00 from $30.00 previously
Roth Capital reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $55.00 from $30.00 previously
Roth Capital reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $55.00 from $30.00 previously
HC Wainwright & Co. reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $48.00 from $30.00 previously
SVB Leerink reiterated coverage of KalVista Pharmaceuticals with a rating of Outperform and set a new price target of $51.00 from $39.00 previously
Jefferies Financial Group reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $61.00 from $34.00 previously
Stifel Nicolaus reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $54.00 from $30.00 previously
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
424B5 - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
10-Q - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
DEFA14A - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
DEF 14A - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 9:10 a.m. EST Jefferies London Healthcare Conference on Thursday, November 21, 2024, at 11:00 a.m. GMT Each presentation will be live webcast on the Company's website at www.kalvista.com. After the presentations, an audio archive will be available on KalVista's website for 30 days. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc. is a global pharmaceutical company whose mission is to develop and deliver life-changing oral medicines f
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted twelve newly-hired employees inducement options to purchase an aggregate of 78,000 shares of KalVista common stock on November 1, 2024 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $10.61 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly in
– First pre-approval royalty acquisition and first equity investment highlight evolving investment strategy – – Up to US$184 million investment brings capital deployment to over US$1 billion since IPO – – Long-term asset in new therapeutic area further increases portfolio duration and diversification – TORONTO, Nov. 4, 2024 /CNW/ - DRI Healthcare Trust (TSX:DHT) (TSX:DHT) (the "Trust"), a global leader in providing financing to advance innovation in the life sciences industry, has acquired a royalty interest in the worldwide net sales of all formulations of sebetralstat from KalVista Pharmaceuticals ("KalVista") for an aggregate purchase price of up to US$179 million, comprised of a US$100 m
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) ("KalVista") today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock at a price of $10.00 per share to certain investors (the "Offering"). The gross proceeds to KalVista from the Offering are expected to be $55 million, before deducting underwriting discounts, commissions and other offering expenses payable by KalVista. Concurrently with the Offering, KalVista has entered into a securities purchase agreement with DRI Healthcare Acquisitions LP ("DRI"), an accredited investor affiliated with DRI Healthcare Trust, pursuant to which KalVista agreed to offer and sell and DRI agreed to purchase 500,000 shares o
–Provides up to $184 million investment to support commercial launch of sebetralstat which, if approved, will be the first and only oral on-demand therapy for HAE – –Strengthens financial position as KalVista establishes global footprint for expected launches in multiple geographies in 2025– KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) ("KalVista"), today announced the closing of a synthetic royalty financing agreement with DRI Healthcare Trust ("DRI") for up to $179 million, comprised of a $100 million upfront payment, a one-time $22 million optional payment upon U.S. product approval, and up to $57 million in a sales-based milestone payment. The proceeds of this transaction will be used
–Phase 3 trial data show that early treatment is correlated with shorter attack duration– – Rigorous comparison of Phase 3 results for oral sebetralstat and pivotal trial results of IV recombinant C1-inhibitor for on-demand treatment of HAE attacks shows no differences in time to beginning of symptom relief – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced the presentation of new sebetralstat data at the American College of Allergy Asthma and Immunology (ACAAI) taking place in Boston, MA from October 24 - 28, 2024. Tim Craig, DO, Professor, Departments of Medicine and Pediatrics, Division of Pulmonary, Allergy and Critical Care Medicine, Penn State Health, and KONFIDENT inv
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that five abstracts have been accepted for e-Poster presentation at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), taking place in Boston, MA from October 24-28. Presentations include: Patient-Reported Anxiety Impacts Utilization of Injectable On-demand Treatment of Hereditary Angioedema Attacks: Cristine Radojicic, Autumn Burnette, Sally van Kooten, Neil Malloy, Markus Heckmann, Hilary Longhurst. Results shared as an e-Poster Presentation on Friday, October 25 at 2:00pm ET, Monitor 20, Exhibit Hall A. On-demand Treatment of Laryngeal Hereditary Angioedema Attacks with Sebe
–New data show effectiveness of sebetralstat in reducing anxiety during attacks; supports need for oral on-demand option to treat attacks earlier and more often– –Patient perspectives spotlight the prevalence of anxiety when faced with administering injectable on-demand therapies– KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that it presented data showing the effectiveness of sebetralstat in reducing anxiety among people experiencing hereditary angioedema (HAE) attacks at the HAEi Global Angioedema Forum (GAF) taking place in Copenhagen, Denmark, October 4 - 5, 2024. These data were generated in the KONFIDENT phase 3 clinical trial, for which the Company disclosed top lin
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted six newly-hired employees inducement options to purchase an aggregate of 31,000 shares of KalVista common stock on October 1, 2024 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $11.39 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly instal
– Submissions support KalVista's mission of building a global footprint for sebetralstat to address the significant unmet need for people with HAE worldwide – – If approved, sebetralstat will be the first, oral on-demand treatment for HAE – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced Marketing Authorization Application (MAA) submissions to the regulatory authorities in the United Kingdom, Switzerland, Australia, and Singapore for sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older. The four MAAs have been submitted via the Access Consort
SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
SC 13D/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
SC 13D/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Mr. Piekos is an experienced public company CFO who brings a demonstrated track record of successfully leading companies across the biotechnology sector. "Brian's deep industry experience and expertise in managing financial and capital strategies makes him a strong addition to KalVista as we prepare for the commercialization of sebetralstat," said Ben Palleiko, Chief Executive Officer at KalVista. "I'm excited to welcome Brian to KalVista, as he shares our commitment to patients and a results-driven approach to business excellence." "I am excited to join
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that William C. Fairey has been appointed to the Company's Board of Directors, effective immediately. Mr. Fairey was most recently the Chief Commercial Officer at MyoKardia, Inc., a clinical stage biopharmaceutical company, and is a business leader with significant experience building markets and launching novel therapeutics to treat specialty and rare/orphan diseases. "We welcome Bill to our Board of Directors," said Ben Palleiko, CEO of KalVista. "His experience in commercial and me
- Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety profile as first oral on-demand therapy for hereditary angioedema - - CEO transition supports ongoing evolution into commercial company - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2024. "This has been an exciting and busy period for KalVista, as we achieved key milestones with the release of our phase 3 KONFIDENT data and th
– Planned transition reflects evolution to commercial company with sebetralstat for HAE – – NDA filing remains on track for H1 2024; Europe and Japan filings H2 2024 – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that Benjamin L. Palleiko, the Company's current President, CBO and CFO, has been appointed as Chief Executive Officer and a director of the Company, effective immediately. In conjunction, Andrew Crockett has submitted his resignation as CEO and a director of the Company. This appointment is the result of a planned tr
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced today the appointment of Nicole Sweeny as Chief Commercial Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230725517894/en/KalVista Chief Commercial Officer Nicole Sweeny (Photo: Business Wire) "As KalVista prepares for our evolution into a commercial organization, we continue to strategically add individuals with deep experience in hereditary angioedema (HAE) product launches and global commercialization," said Andrew Cro
– Current Board Chairman Martin Edwards, M.D. to Retire in Planned Transition - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that the Board of Directors has appointed current member Brian J.G. Pereira, M.D., as Chairman, effective immediately. In conjunction, current Chairman Martin Edwards, M.D. has resigned from the Board in a planned transition concurrent with the Company's annual meeting. "We are pleased that Brian has agreed to take the Chairman role at this critical time," said Andrew Crockett, Chief Executive Officer of K
– Sebetralstat Phase 3 KONFIDENT and KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track – – Formal Notification Received of Sebetralstat EU Orphan Drug Status – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal year ended April 30, 2022. "We are pleased with the progress we have made over the last fiscal year in the development of the candidates in our oral hereditary angioedema franchise," said Andrew Crockett, Chief Executive Officer of KalVista. "We are me
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today the appointment of Paul K. Audhya, MD, MBA, as Chief Medical Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210503005196/en/KalVista CMO Paul Audhya (Photo: Business Wire) "As we advance our oral hereditary angioedema franchise in the clinic, KalVista will be strategically growing by adding individuals with deep experience in late-stage drug development and global commercialization," said Andrew Crockett, Chief Executive O
– Chair and board member Michael Wolf Jensen will not stand for re-election at 2021 Annual General Meeting – – Board of Directors intends to appoint Dr. Albert Cha to serve as Chair after 2021 AGM – COPENHAGEN, Denmark, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced a planned board transition at the 2021 Annual General Meeting (AGM). Michael Wolf Jensen informed the Board of Directors (the Board) that he will not stand for re-election to the Board at the next Annual General Meeting. Mr. Jensen wi